Patents by Inventor Simon Lempriere Westbrook

Simon Lempriere Westbrook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080234280
    Abstract: This invention relates to the use of an MC4 receptor agonist compound for the manufacture of a medicament for the treatment of lower urinary tract dysfunction.
    Type: Application
    Filed: July 20, 2006
    Publication date: September 25, 2008
    Inventors: Gordon McMurray, Stephen Charles Phillips, Simon Lempriere Westbrook
  • Publication number: 20040167095
    Abstract: The invention relates to the use of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five (cGMP PDE V) inhibitor for increasing fecundity in a mammal by one or more of (a) promoting the growth of an oocyte, zygote, blastocyst, embryo and/or fetus, (b) increasing the rate or probability of survival of an embryo and/or fetus and (c) increasing the birth weight of a progeny, or for increasing milk productivity.
    Type: Application
    Filed: February 12, 2004
    Publication date: August 26, 2004
    Inventors: Simon Lempriere Westbrook, Johannes Fridrich Zanzinger
  • Patent number: 6743799
    Abstract: The invention relates to the use of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five (cGMP PDE V) inhibitor for increasing fecundity in a mammal by one or more of (a) promoting the growth of an oocyte, zygote, blastocyst, embryo and/or foetus, (b) increasing the rate or probability of survival of an embryo and/or foetus and (c) increasing the birth weight of a progeny, or for increasing milk productivity.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: June 1, 2004
    Assignee: Pfizer Inc.
    Inventors: Simon Lempriere Westbrook, Johannes Fridrich Zanzinger
  • Publication number: 20040029891
    Abstract: The present invention relates to the use of a pyrazolopyrimidinone PDE5 inhibitor such as sildenafil for the treatment of polycystic ovary syndrome.
    Type: Application
    Filed: September 2, 2003
    Publication date: February 12, 2004
    Applicant: Pfizer Inc.
    Inventors: Mahmoud Nizar Ghazzi, Nandan Parmanand Koppiker, Simon Lempriere Westbrook
  • Patent number: 6548508
    Abstract: The invention relates to the use of a cyclic guanosine 3′, 5′-monophosphate phosphodiesterase type five (cGMP PDE V) inhibitor for increasing fecundity in a mammal by one or more of (a) promoting the growth of an oocyte, zygote, blastocyst, embryo and/or foetus, (b) increasing the rate or probability of survival of an embryo and/or foetus and (c) increasing the birth weight of a progeny, or for increasing milk productivity.
    Type: Grant
    Filed: October 18, 2001
    Date of Patent: April 15, 2003
    Assignee: Pfizer, Inc.
    Inventors: Simon Lempriere Westbrook, Johannes Fridrich Zanzinger
  • Publication number: 20030018036
    Abstract: The invention relates to the use of a cyclic guanosine 3′, 5′-monophosphate phosphodiesterase type five (cGMP PDE V) inhibitor for increasing fecundity in a mammal by one or more of (a) promoting the growth of an oocyte, zygote, blastocyst, embryo and/or fetus, (b) increasing the rate or probability of survival of an embryo and/or foetus and (c) increasing the birth weight of a progeny, or for increasing milk productivity.
    Type: Application
    Filed: October 18, 2001
    Publication date: January 23, 2003
    Inventors: Simon Lempriere Westbrook, Johannes Fridrich Zanzinger